Clinical Trials Enhance Care for Advanced Gastrointestinal Cancers
Clinical trials improve care and access to novel treatments for advanced gastrointestinal cancers, says Dr. Michael Pishvaian.
Related Articles
When a “Thinking of You” Card Isn’t the Right Support for a Patient
Those of us who’ve survived our cancer treatment journeys need to be role models to those who follow us.
FDA Approves Monjuvi With Revlimid and Rituxan for Follicular Lymphoma
The FDA approved Monjuvi with Revlimid and Rituxan for R/R follicular lymphoma after it showed significantly longer progression-free survival vs placebo.
I’m a Survivor: The Day I Finally Believed It
I finally felt like a survivor the day I heard my 18-month scans were clear, shifting from fear to faith and realizing I was not…
The Person Behind Their Diagnosis: Understanding the Patient
Dr. Joshua Sabari and Jackie Herigodt discuss the Imerman Angels organization and the importance of recognizing the person behind their cancer diagnosis.
Atebimetinib Combo Shows 94% 6-Month Survival in Pancreatic Cancer
Atebimetinib with modified chemo led to 94% 6-month survival rates in first-line pancreatic cancer, with durable responses and a favorable safety profile.
Diving Into Every FDA Drug Approval for Cancer Care During May 2025
Here is a recap of every FDA approval announced by the regulatory agency in the month of May, spanning various cancer types.
FDA Approves Brukinsa Tablet For Various Blood Cancers
FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as capsules.
From Navigating the Unknown to Building a Movement: My DCIS Journey
The bad news is you have ductal carcinoma in situ. The good news is that DCIS is the best type of breast cancer to get.
How Insurance Red Tape Threatens Timely Cancer Care
A study explores how prior authorization requirements; coverage stoppages and other red tape can generate barriers to life saving therapies in cancer care.
Understanding the Importance of the DESTINY-Breast09 Trial in HER2+ Breast Cancer
Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic breast cancer should know.